netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.03  Expand sub section  Antisecretory drugs and mucosal protectants
01.03.01  Expand sub section  H2-receptor antagonists
Ranitidine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Ranitidine Hydrochloride Oral Solution 75mg/5ml S/F
Ranitidine Hydrochloride Tablet 150mg
Ranitidine Hydrochloride Tablet 300mg 

 
   
01.03.02  Expand sub section  Selective antimuscarinics
01.03.03  Expand sub section  Chelates and complexes
Sucralfate (Antepsin)
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Amber

Tablet 1g, Suspension 500mg/5ml

For Specialist Initiation Only

 
   
01.03.04  Expand sub section  Prostaglandin analogues to top
Misoprostol (Cytotec)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Misoprostol 200mg tablet


For specialist initiation only

 
   
01.03.05  Expand sub section  Proton pump inhibitors (PPIs)
Omeprazole 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Omeprazole Capsule E/C 10mg
Omeprazole Capsule E/C 20mg
Omeprazole Tablet Dispersible E/C 10mg (E/C Pellets)
Omeprazole Tablet Dispersible E/C 20mg (E/C Pellets)

1st line PPI (except for MUPs)

 
   
Lansoprazole 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Lansoprazole Capsules 15mg (E/C Granules)
Lansoprazole Capsules 30mg (E/C Granules)
Lansoprazole FasTab Orodispersible Tablet 15mg
Lansoprazole FasTab Orodispersible Tablet 30mg

2nd line PPI

(Orodispersible 1st line in patients with enteral feeding tubes or swallowing difficulties)

 
   
Esomeprazole granules

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Esomeprazole 10mg gastro-resistant granules sachets

Restriction: For use in paediatric patients for gastro-oesophageal reflux disease only

 
   
01.03.06  Expand sub section  Other ulcer-healing drugs
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary